Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-408-1300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$49.99 million
Profitability
Miscellaneous
Employees215
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics Inc (NASDAQ:NEOS) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. The business earned $15.39 million during the quarter, compared to analysts' expectations of $18.90 million. View Neos Therapeutics' Earnings History.
When is Neos Therapeutics' next earnings date?
What price target have analysts set for NEOS?
3 equities research analysts have issued 1 year price objectives for Neos Therapeutics' shares. Their predictions range from $6.00 to $20.00. On average, they anticipate Neos Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 494.1% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.
What is the consensus analysts' recommendation for Neos Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.
What are Wall Street analysts saying about Neos Therapeutics stock?
Here are some recent quotes from research analysts about Neos Therapeutics stock:
- 1. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (4/18/2019)
- 2. Cantor Fitzgerald analysts commented, ". We hosted two days of meetings with NEO’s CEO Jerry McLaughlin and CFO Richard Eisenstadt. The takeaways from these meetings underscore our OW rating and 12-month PT of $20 for NEOS stock. These meetings increased our confidence that NEOS’s restructuring plan to optimize value over volume in ADHD, and expand its pipeline are both underappreciated. Therefore, continued success with the sales of its key ADHD drugs (Adzenys ER), as well as pipeline advancements (NT-0400 and NT-0502), should drive upwards earnings revisions to levels not reflected in the consensus and move NEOS’s stock higher." (3/27/2019)
Has Neos Therapeutics been receiving favorable news coverage?
News headlines about NEOS stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neos Therapeutics earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the next few days.
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include Flexion Therapeutics (FLXN), MediciNova (MNOV), Aptorum Group (APM), Innate Pharma (IPHYF), Albireo Pharma (ALBO), Sinovac Biotech (SVA), Kezar Life Sciences (KZR), ImmunoGen (IMGN), Akorn (AKRX), Beyondspring (BYSI), Geron (GERN), Keryx Biopharmaceuticals (KERX), Kindred Biosciences (KIN), Savara (SVRA) and XBiotech (XBIT).
What other stocks do shareholders of Neos Therapeutics own?
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Mr. Richard I. Eisenstadt, Chief Financial Officer (Age 61)
- Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 51)
- Mr. John M. Limongelli, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
- Mr. Darren Heath, VP of Sales
- Mr. Russ McMahen, Sr. VP of R&D
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
Who are Neos Therapeutics' major shareholders?
Neos Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.10%) and Livingston Group Asset Management CO operating as Southport Capital Management (0.05%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.
Which institutional investors are buying Neos Therapeutics stock?
NEOS stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Livingston Group Asset Management CO operating as Southport Capital Management. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.
How do I buy shares of Neos Therapeutics?
Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of NEOS stock can currently be purchased for approximately $2.02.
How big of a company is Neos Therapeutics?
Neos Therapeutics has a market capitalization of $100.41 million and generates $49.99 million in revenue each year. The company earns $-51,670,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.
What is Neos Therapeutics' official website?
How can I contact Neos Therapeutics?
Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]
MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
